Long-term use of anagrelide in young patients with essential thrombocythemia.
about
Headache in essential thrombocythaemiaReticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapyThe Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential ThrombocythemiaAnagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profileCurrent trends in essential thrombocythaemiaTreatment of polycythemia vera and essential thrombocythemia: the role of pipobromanThrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemiaAnagrelide for the treatment of essential thrombocythemia: a survey among European hematologists/oncologistsSevere hypersensitivity pneumonitis associated with anagrelide.Primary and secondary thrombocytosis in childhood.How I treat essential thrombocythemia.Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia.A critical review of anagrelide therapy in essential thrombocythemia and related disorders.Essential thrombocythaemia: challenges and evidence-based management.Anagrelide for control of thrombocytosis due to myeloproliferative disorders.Cardiovascular safety of anagrelide in healthy subjects: effects of caffeine and food intake on pharmacokinetics and adverse reactionsAnagrelide: 20 years later.Postsplenectomy reactive thrombocytosis.Role of platelet counts in the management of essential thrombocythemia: experience with anagrelide.Treatment options for essential thrombocythemia and polycythemia vera.Target hematologic values in the management of essential thrombocythemia and polycythemia vera.Management of side effects of BCR/ABL-negative chronic myeloproliferative neoplasm therapies. Focus on anagrelide.Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?Influence of platelet and white blood cell counts on major thrombosis - analysis from a patient registry in essential thrombocythemia.TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders.Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients.Open-label, dose-titration and continuation study to assess efficacy, safety, and pharmacokinetics of anagrelide in treatment-naïve Japanese patients with essential thrombocythemia.Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis.Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: occurrence of leukaemic evolution.Anagrelide-induced visual hallucinations in a patient with essential thrombocythemia.Anagrelide treatment in 52 patients with chronic myeloproliferative diseases.Essential thrombocythemia treatment algorithm 2018.Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study.Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status.
P2860
Q24629739-BB21D62E-3F49-4F5C-A6AB-DAE454F8EFACQ24631288-45C169E6-DD36-4870-BBF5-54CC3EA981C6Q28074777-C3400EB3-7F9B-4C3E-B631-BB3BF87263C2Q28171087-54938187-DD1F-4D02-B55E-04432ACB6698Q28193180-9E91F54A-85F2-460E-8765-EBB635466B90Q28210858-9BB35803-48D8-480C-AF52-C83D32D705E9Q28213633-B1BEBF24-E647-4AC2-9923-907DAD208322Q28307195-A3ED5C24-E077-4B4D-9745-D571F13ED7B4Q34536252-243930BF-FF39-473D-A239-5EE462B05835Q34556544-2BD33125-0433-4B91-83E9-43683CE5777CQ35132271-DC53CE20-E089-4842-BA5F-4FC527503358Q35841596-1B7D3D05-7C0E-42F7-81C3-2AF3AD92652DQ36194626-83325A2F-55C6-4CCF-93A3-ED4811767858Q36200476-123B45D7-D8F6-4CAE-825D-C368D7FEDA0DQ36429566-AF713162-21B4-40A5-84E8-031ADD30E71FQ36650181-297EE9F3-D6BD-4B32-ACBB-3E72F2535F12Q37357291-D82212EA-C6EA-43BE-9E22-EEE947149DAAQ37377509-7B2C8C24-2BA6-4993-BED5-0B56CB22EAD1Q37810089-5039122A-52FD-435A-9A58-20E33DA910DBQ37810107-5A0BCF42-AE37-4B24-B6B4-F9382C8C8BE2Q38210664-2E8DF3D1-8F40-4535-90D4-D863D85F9D9BQ38586505-7F562198-549B-4D94-962D-C38CC70D128EQ39041471-7CF71394-0116-4D68-9C1C-FF27AF428D6FQ39869975-E91E32BA-1AE0-4930-9143-06817E292140Q42085145-F38C733A-B40F-4197-B042-65E6E1B9ED28Q42552869-AA2F0891-D40D-4C04-B17F-345C733850F2Q42685892-DA03E0B2-DA40-4BFD-BA0D-E0A730B407D6Q43910566-E27FB61B-D969-413C-A347-CA79FEF24AF7Q44655441-F95C9152-5997-4F73-80AB-3233439E971CQ45002812-51E1DD37-1D19-4B92-B1CB-CB92E7065CB6Q45107227-2B5CB7D0-E0C5-487B-8BB7-530D30D3429EQ47565721-27416DF2-06DE-4B2F-9529-ABAA43D1F879Q47699454-831DADC6-C75A-40A2-858E-F98925794F3CQ54262553-4393984F-E863-4112-90B7-D482EDDF90FF
P2860
Long-term use of anagrelide in young patients with essential thrombocythemia.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Long-term use of anagrelide in young patients with essential thrombocythemia.
@ast
Long-term use of anagrelide in young patients with essential thrombocythemia.
@en
type
label
Long-term use of anagrelide in young patients with essential thrombocythemia.
@ast
Long-term use of anagrelide in young patients with essential thrombocythemia.
@en
prefLabel
Long-term use of anagrelide in young patients with essential thrombocythemia.
@ast
Long-term use of anagrelide in young patients with essential thrombocythemia.
@en
P356
P1433
P1476
Long-term use of anagrelide in young patients with essential thrombocythemia.
@en
P2093
E C Storen
P304
P356
10.1182/BLOOD.V97.4.863
P407
P577
2001-02-01T00:00:00Z